Improving Lives through

Cell and Gene Therapy

Cure Genetics
Committed to the development of gene and cell therapy for oncology and genetic diseases
Cure Genetics, is a clinical-stage company dedicated to developing cell and gene therapies for solid tumors and genetic diseases. Through our innovative AIMS CAR-NKT and VELPTM AAV platforms, Cure Genetics has developed a differentiated pipeline. By leveraging global collaborations and out-license, we actively drive the research & development, and commercialization of innovative drugs. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapies.

Explore

Focus
Cure Genetics focus on the cell and gene therapy for solid tumors and genetic diseases.

Explore

Our Science
Cure Genetics has two unique technology platforms:

AIMS CAR-NKT, which has demonstrated its good safety profile in the first FIC pipeline targeting clear cell renal carcinoma in clinical studies by enhancing solid tumor infiltration, modulating the tumor microenvironment, and extending sustained expansion. It is also being expanded into other autologous/allogeneic/in vivo pipelines.

VELPTM platform, through the effective diversity of libraries, excellent library packaging compatibility, and a combination of DNA enrichment-RNA signal detection technologies, has completed licensing collaborations with MNCs and Biotech companies such as Boehringer Ingelheim (BI), and is actively advancing the transformation of products targeting the nervous system, heart, and kidneys.

Explore

News

More

We keep you updated with the latest company and industry insights
Cure Genetics announced the interim data of CAR-NKT product for patients withRCC in an oral presentation at the 27th ASGCT
2024.05.20
Cure Genetics announced the interim data of CAR-NKT product for patients withRCC in an oral presentation at the 27th ASGCT

This marked the first human trial using CAR-NKT therapy for RCC, demonstrating its good safety profile and anti-tumor activity.

Cure Genetics Awarded Third Place in the 2024 Biomedical Pitch Competition
2024.05.10
Cure Genetics Awarded Third Place in the 2024 Biomedical Pitch Competition

Cure Genetics distinguished itself from nearly a hundred international projects and was awarded third place in the 2024 Biomedical Pitch Competition

 Cure Genetics to Unveil Groundbreaking Achievements at 2024 ASGCT Annual Meeting
2024.05.10
Cure Genetics to Unveil Groundbreaking Achievements at 2024 ASGCT Annual Meeting

Cure Genetics will present for the first time the latest advancements of the CAR-NKT product CGC729 for RCC treatment through an oral presentation at the 2024 ASGCT Annual Meeting, and will also showcase four research findings related to the development of AAV serotypes.

A novel PD-1-IL-2v bispecific molecule for cancer immunotherapy developed by Cure Genetics has been published in Frontiers in Immunology
2024.05.10
A novel PD-1-IL-2v bispecific molecule for cancer immunotherapy developed by Cure Genetics has been published in Frontiers in Immunology

The journal Frontiers in Immunology recently reported on Cure Genetics' developed CGC-602 bispecific antibody molecule, which targets both PD-1 and IL-2. The IL-2v component is a variant derived from wild-type IL-2.

Dr. Pengcheng Zhou Joins Cure Genetics as Vice President of Gene Therapy R&D
2023.10.10
Dr. Pengcheng Zhou Joins Cure Genetics as Vice President of Gene Therapy R&D

Cure Genetics is delighted to announce that Dr. Pengcheng Zhou has joined the company on August 21, 2023, taking on the role of Vice President of Gene Therapy Research and Development, responsible for the research and translation of the company's gene therapy products. Dr. Zhou brings with him decades of extensive experience in the AAV gene therapy domain, showcasing remarkable achievements at leading academic institutions and renowned companies including Harvard University, Voyager, Luye Pharma, and Frontera Therapeutics.

Dr. Ren Li Appointed Chief Technology Officer at Cure Genetics
2023.09.15
Dr. Ren Li Appointed Chief Technology Officer at Cure Genetics

Cure Genetics is delighted to announce that Dr. Li Ren has joined the company recently, taking on the role of Chief Technology Officer in Cell Therapy.

Cure Genetics and Frametact Limited Enter collaborative development and Licensing Agreement to Develop Gene
2023.09.14
Cure Genetics and Frametact Limited Enter collaborative development and Licensing Agreement to Develop Gene

Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement.

Dr. Shawn He Named Chief Scientific Officer at Cure Genetics
2023.08.01
Dr. Shawn He Named Chief Scientific Officer at Cure Genetics

Cure Genetics is delighted to announce that Dr. Shawn He will officially take up his post as the Chief Scientific Officer (CSO) in cell therapy on August 1, 2023. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines.

Robert R. Ruffolo Joins CureGenetics's Scientific Advisory Board
2022.04.01
Robert R. Ruffolo Joins CureGenetics's Scientific Advisory Board

In April 2022, Suzhou, China, Cure Genetics, a biotechnology company focusing on development of cutting-edge gene and cell therapies, announced that Dr. Robert R. Ruffolo has joined its Scientific Advisory Board (SAB). Where he will provide scientific guidance to Cure Genetics technology platform and R&D pipeline, as well as assisting the Company’s global partnership effort.

Genevide, an incubation project of Cure Genetics, completed an angel round financing of RMB 50 million
2022.01.14
Genevide, an incubation project of Cure Genetics, completed an angel round financing of RMB 50 million

Recently, Genevide, an independent incubation company from Cure Genetics’s former molecular diagnostics business, announced the completion of a RMB 50 million angel round of financing led by Bioventure, co-invested by Qiming Ventures. Dr. Qiushi Li, former co-founder and COO of Cure Genetics, is named the co-founder and CEO of Genevide. “Genevide has built an Enzymes-mediated Duplex Exponential Amplification (EmDEATM) nPOCT technology platform with independent intellectual property portfolio using an innovative molecular enzyme cycle screening system based on enzyme characterization methods. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products. “ Dr. Qiushi Li, Co-Founder and CEO of Genevide said.

Cure Genetics Completed $60 Million Series B Financing
2022.01.05
Cure Genetics Completed $60 Million Series B Financing

On January 5, 2022, Cure Genetics Biotechnology Co., Ltd. (hereinafter referred to as "CureGenetics") announced the completion of a US$60 million Series B financing. This round of financing was led by strategic investor Advantech Capital, followed by Oriza Holdings, BOCG and Qiming Venture Partners, with China Renaissance acting as the exclusive financial advisor.

Boehringer Ingelheim and Cure Genetics Collaborate to Develop Novel AAV Vectors for Next Generation Liver Targeted Gene Therapy
2021.01.18
Boehringer Ingelheim and Cure Genetics Collaborate to Develop Novel AAV Vectors for Next Generation Liver Targeted Gene Therapy

Boehringer Ingelheim (BI) and Cure Genetics Co., Ltd (Cure Genetics) today announced a collaboration to develop novel adeno-associated viral (AAV) vectors for next-generation gene therapy through Cure Genetics's proprietary VELPTM platform. This new collaboration combines BI's experience in disease mechanism research and gene therapy development with Cure Genetics's expertise in viral library construction and high-efficient in vivo AAV screening, providing patients with potentially safer and more efficient novel AAV serotypes.